Venous Thromboembolism (DVT/PE) Prevention Support Protocol
Primary Stack
Core supplements with strongest evidenceMild antiplatelet effects; may reduce blood viscosity and support cardiovascular health
Deficiency associated with increased VTE risk; may affect coagulation factors
Supporting Stack
Additional supplements for enhanced resultsFibrinolytic enzyme that may help dissolve fibrin; studied for cardiovascular health
Supporting Studies (1)
Antioxidant with mild antiplatelet effects
Supporting Studies (1)
Supports cardiovascular health; may have mild antiplatelet effects
Supporting Studies (1)
Deficiency elevates homocysteine, a VTE risk factor
Supporting Studies (1)
Lowers homocysteine levels; deficiency associated with increased VTE risk
Supporting Studies (1)
Flavonoid with antiplatelet and anti-inflammatory properties
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Venous thromboembolism (VTE) includes deep vein thrombosis (DVT, blood clots in deep veins, usually legs) and pulmonary embolism (PE, clots that travel to the lungs). VTE affects hundreds of thousands of people yearly and can be fatal (PE is a leading cause of preventable hospital death). Risk factors include immobility (travel, hospitalization, surgery), cancer, pregnancy, estrogen use, obesity, genetic clotting disorders, and prior VTE.
CRITICAL: VTE is a medical emergency. DVT symptoms include leg swelling, pain, warmth, and redness. PE symptoms include sudden shortness of breath, chest pain (worse with breathing), rapid heart rate, coughing up blood, and feeling faint. If you suspect VTE, seek immediate medical care. Treatment requires anticoagulation (blood thinners like warfarin, DOACs) - this is NOT a condition to manage with supplements alone. These supplements may support cardiovascular health and potentially reduce recurrence risk as adjuncts, but they CANNOT replace anticoagulation. IMPORTANT: Many supplements affect bleeding - always discuss with your doctor before taking any supplements if you're on blood thinners.
* Omega-3 Fatty Acids have mild antiplatelet effects and may reduce blood viscosity. They're generally considered safe at moderate doses with anticoagulants but discuss with your doctor.
* Vitamin D deficiency is associated with increased VTE risk. Maintaining adequate levels may be protective, though this is still being studied.
* Nattokinase is a fibrinolytic enzyme from fermented soybeans that has been studied for its clot-dissolving properties. AVOID if on any anticoagulant - serious bleeding risk.
* Vitamin E has mild antiplatelet effects. Keep doses moderate.
* B12 and Folate - deficiencies elevate homocysteine, which is associated with VTE risk.
* Magnesium supports cardiovascular health.
* Quercetin has antiplatelet properties - use cautiously with blood thinners.
Expected timeline: Prevention is ongoing. For those with prior VTE, anticoagulation duration depends on circumstances (provoked vs unprovoked, risk factors). These supplements support long-term cardiovascular health.
Clinical Perspective
Venous thromboembolism: DVT (usually lower extremity) + PE. Incidence: ~1-2/1000/year. Mortality: PE ~10-30% if untreated. Virchow's triad: stasis, endothelial injury, hypercoagulability. Risk factors: immobility (surgery, travel >4 hours), malignancy, estrogen (OCP, HRT, pregnancy), hereditary thrombophilia (Factor V Leiden, prothrombin mutation), antiphospholipid syndrome, prior VTE, obesity, age.
CRITICAL: Diagnosis: DVT - compression ultrasonography; PE - CT pulmonary angiography (CTPA), V/Q scan. D-dimer: useful for ruling out with low pretest probability. Treatment: Anticoagulation - DOACs first-line for most (apixaban, rivaroxaban, edoxaban, dabigatran); warfarin still used; LMWH for cancer-associated VTE (or DOAC). Duration: 3 months minimum; extended for unprovoked, recurrent, cancer. IVC filter: only for anticoagulation contraindication. Supplements are NOT anticoagulant replacement. Drug interactions: CRITICAL - many supplements affect coagulation and interact with anticoagulants.
* Omega-3 Fatty Acids (B-grade): Reduced platelet aggregation; lower viscosity. Systematic review: VTE (PMID: 23265678). Meta-analysis: hemostatic effects (PMID: 21345479). 1-2g daily. Mild bleeding effect - discuss with provider.
* Vitamin D (B-grade): Deficiency association with VTE. Systematic review/meta-analysis: (PMID: 28371839). Study: thrombosis risk (PMID: 23913661). 2000-4000 IU daily.
* Nattokinase (C-grade): Fibrinolytic; thrombolytic. Systematic review: (PMID: 28763875). 2000-4000 FU daily. CONTRAINDICATED with anticoagulants.
* Vitamin E (C-grade): Antiplatelet effects. Review: thrombosis (PMID: 25747538). 100-200 IU daily. Higher doses increase bleeding.
* Magnesium (C-grade): Cardiovascular support. Review: (PMID: 28150472). 300-400mg daily.
* Vitamin B12 (C-grade): Homocysteine lowering. Meta-analysis: VTE association (PMID: 17636084). 1000mcg daily if deficient.
* Folate (C-grade): Homocysteine lowering. Meta-analysis: vascular disease (PMID: 18403564). 400-800mcg daily.
* Quercetin (C-grade): Antiplatelet flavonoid. Review: hemostasis (PMID: 26808877). 500mg BID. Use caution with anticoagulants.
Biomarker targets: INR (if on warfarin), anti-Xa levels (if indicated), D-dimer (elevated suggests ongoing clot burden), homocysteine (if B vitamin deficiency), vitamin D level.
Protocol notes: DOAC drug interactions: AVOID - nattokinase, high-dose vitamin E, ginkgo, high-dose garlic, dong quai. CAUTION - omega-3, quercetin, ginger (additive bleeding risk). Warfarin interactions: vitamin K (antagonizes warfarin - keep intake consistent, not eliminated); ginkgo, garlic, ginger, omega-3 may increase INR; CoQ10 may decrease INR. Prevention: graduated compression stockings during travel; hydration; calf exercises during immobility; early mobilization post-surgery. Post-thrombotic syndrome: compression stockings debated but may help symptoms. Thrombophilia testing: not routinely recommended; consider for young, unprovoked, unusual site, family history. Aspirin: after anticoagulation stops, aspirin may reduce recurrence - discuss with hematologist. Exercise: beneficial once acute clot stabilized. Flying: increased risk on long-haul flights >4 hours; compression stockings, hydration, movement help. Cancer screening: consider after unprovoked VTE in older adults.